Article Text

Download PDFPDF
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab
  1. Francesco Muratore1,
  2. Carlo Salvarani1,2
  1. 1 Unit of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
  2. 2 Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
  1. Correspondence to Dr Francesco Muratore, Unit of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia 42123, Italy; francesco.muratore{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In recent years there has been growing interest in the use of tocilizumab for the treatment of large vessel vasculitis. Although the primary endpoint (time to relapse) was not met in the first randomised, placebo-controlled trial evaluating the efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis, the results suggested favour for tocilizumab over placebo without new safety concerns.1 In this journal, three cases of Takayasu arteritis progression during tocilizumab treatment have been described.2 3 We report one additional patient with disease progression despite tocilizumab therapy.

A 25-year-old woman presented with …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors Both authors were involved in the preparation of the manuscript and have approved the manuscript and this submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.